| High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types DJ McGrail, PG Pilié, NU Rashid, L Voorwerk, M Slagter, M Kok, ... Annals of Oncology 32 (5), 661-672, 2021 | 404 | 2021 |
| Inflammatory breast cancer biology: the tumour microenvironment is key B Lim, WA Woodward, X Wang, JM Reuben, NT Ueno Nature Reviews Cancer 18 (8), 485-499, 2018 | 229 | 2018 |
| Androgen receptor function and androgen receptor–targeted therapies in breast cancer: a review M Kono, T Fujii, B Lim, MS Karuturi, D Tripathy, NT Ueno JAMA oncology 3 (9), 1266-1273, 2017 | 163 | 2017 |
| Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? F Le Du, BL Eckhardt, B Lim, JK Litton, S Moulder, F Meric-Bernstam, ... Oncotarget 6 (15), 12890, 2015 | 133 | 2015 |
| Advancing cancer research and medicine with single-cell genomics B Lim, Y Lin, N Navin Cancer cell 37 (4), 456-470, 2020 | 132 | 2020 |
| Discovery and clinical introduction of first-in-class imipridone ONC201 JE Allen, CLB Kline, VV Prabhu, J Wagner, J Ishizawa, N Madhukar, ... Oncotarget 7 (45), 74380, 2016 | 123 | 2016 |
| Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer T Fujii, T Kogawa, W Dong, AA Sahin, S Moulder, JK Litton, D Tripathy, ... Annals of Oncology 28 (10), 2420-2428, 2017 | 108 | 2017 |
| Targeting TRAIL in the treatment of cancer: new developments B Lim, JE Allen, VV Prabhu, MK Talekar, NK Finnberg, WS El-Deiry Expert opinion on therapeutic targets 19 (9), 1171-1185, 2015 | 105 | 2015 |
| Current treatment of early breast cancer: adjuvant and neoadjuvant therapy E Miller, HJ Lee, A Lulla, L Hernandez, P Gokare, B Lim F1000Research 3 (198), 198, 2014 | 93 | 2014 |
| International consensus on the clinical management of inflammatory breast cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference NT Ueno, JRE Fernandez, M Cristofanilli, B Overmoyer, D Rea, ... Journal of Cancer 9 (8), 1437, 2018 | 91 | 2018 |
| Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites WS El-Deiry, N Vijayvergia, J Xiu, A Scicchitano, B Lim, NS Yee, ... Cancer biology & therapy 16 (12), 1726-1737, 2015 | 90 | 2015 |
| Breast tumours maintain a reservoir of subclonal diversity during expansion DC Minussi, MD Nicholson, H Ye, A Davis, K Wang, T Baker, M Tarabichi, ... Nature 592 (7853), 302-308, 2021 | 87 | 2021 |
| Inflammatory breast cancer: a proposed conceptual shift in the UICC–AJCC TNM staging system TM Fouad, AMG Barrera, JM Reuben, A Lucci, WA Woodward, ... The Lancet Oncology 18 (4), e228-e232, 2017 | 83 | 2017 |
| Targeting the interplay between epithelial-to-mesenchymal-transition and the immune system for effective immunotherapy R Soundararajan, JJ Fradette, JM Konen, S Moulder, X Zhang, ... Cancers 11 (5), 714, 2019 | 82 | 2019 |
| Lung mesenchymal cells elicit lipid storage in neutrophils that fuel breast cancer lung metastasis P Li, M Lu, J Shi, Z Gong, L Hua, Q Li, B Lim, XHF Zhang, X Chen, S Li, ... Nature immunology 21 (11), 1444-1455, 2020 | 70 | 2020 |
| Current challenges of metastatic breast cancer B Lim, GN Hortobagyi Cancer and Metastasis Reviews 35, 495-514, 2016 | 65 | 2016 |
| Inflammatory breast cancer: what to know about this unique, aggressive breast cancer A Menta, TM Fouad, A Lucci, H Le-Petross, MC Stauder, WA Woodward, ... Surgical Clinics 98 (4), 787-800, 2018 | 64 | 2018 |
| Novel therapeutic strategies in the treatment of triple-negative breast cancer K Oualla, HM El-Zawahry, B Arun, JM Reuben, WA Woodward, ... Therapeutic advances in medical oncology 9 (7), 493-511, 2017 | 63 | 2017 |
| Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer HJ Lee, IA Park, SY Park, AN Seo, B Lim, Y Chai, IH Song, NE Kim, ... Breast Cancer Research and Treatment 145, 615-623, 2014 | 55 | 2014 |
| Safety and efficacy of panitumumab plus neoadjuvant chemotherapy in patients with primary HER2-negative inflammatory breast cancer N Matsuda, X Wang, B Lim, S Krishnamurthy, RH Alvarez, JS Willey, ... JAMA oncology 4 (9), 1207-1213, 2018 | 54 | 2018 |
James ReubenProfessor, University of Texas MD Anderson Cancer Center在 mdanderson.org 的电子邮件经过验证
